De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Becton Dickinson Beheer

Beheer criteriumcontroles 3/4

De CEO Becton Dickinson's is Tom Polen, benoemd in Apr2017, heeft een ambtstermijn van 7.5 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 17.31M, bestaande uit 7.6% salaris en 92.4% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.02% van de aandelen van het bedrijf, ter waarde $ 14.20M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.8 jaar en 7 jaar.

Belangrijke informatie

Tom Polen

Algemeen directeur

US$17.3m

Totale compensatie

Percentage CEO-salaris	7.6%
Dienstverband CEO	7.5yrs
Eigendom CEO	0.02%
Management gemiddelde ambtstermijn	2.8yrs
Gemiddelde ambtstermijn bestuur	7yrs

Recente managementupdates

Recent updates

Why We're Not Concerned About Becton, Dickinson and Company's (NYSE:BDX) Share Price

Jul 16

An Intrinsic Calculation For Becton, Dickinson and Company (NYSE:BDX) Suggests It's 36% Undervalued

Jun 27

Is Becton Dickinson (NYSE:BDX) Using Too Much Debt?

May 24

Becton, Dickinson and Company: Stagnating All Along

May 16

Investors Still Waiting For A Pull Back In Becton, Dickinson and Company (NYSE:BDX)

Mar 23

Estimating The Fair Value Of Becton, Dickinson and Company (NYSE:BDX)

Feb 29

Becton Dickinson's (NYSE:BDX) Conservative Accounting Might Explain Soft Earnings

Feb 08

Becton, Dickinson and Company Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Feb 03

These 4 Measures Indicate That Becton Dickinson (NYSE:BDX) Is Using Debt Reasonably Well

Feb 01

Becton, Dickinson: 4 Reasons To Buy This Growth At A Reasonable Price Play

Jan 22

Becton Dickinson's (NYSE:BDX) Shareholders Will Receive A Bigger Dividend Than Last Year

Nov 30

Becton, Dickinson And Company: Strong Q4 But Clouded By 75bps Growth Headwind From China In FY24

Nov 13

Becton Dickinson's (NYSE:BDX) Upcoming Dividend Will Be Larger Than Last Year's

Nov 12

Becton, Dickinson and Company's (NYSE:BDX) Intrinsic Value Is Potentially 26% Above Its Share Price

Nov 06

With EPS Growth And More, Becton Dickinson (NYSE:BDX) Makes An Interesting Case

Oct 05

Becton, Dickinson Stock Is A Hold, Here's Why

Oct 04

Becton, Dickinson: Ahead Of Schedule, Undervalued, And With Some Positive Drivers

Aug 30

We Think Becton Dickinson (NYSE:BDX) Can Stay On Top Of Its Debt

Aug 13

Estimating The Intrinsic Value Of Becton, Dickinson and Company (NYSE:BDX)

Jul 28

Here's Why We Think Becton Dickinson (NYSE:BDX) Is Well Worth Watching

Jun 22

Becton, Dickinson and Company: Still Not Very Healthy

Jun 20

Becton, Dickinson: Business Should Beat H2 2023 Expectations

Jun 08

These 4 Measures Indicate That Becton Dickinson (NYSE:BDX) Is Using Debt Reasonably Well

Apr 22

Is Now The Time To Put Becton Dickinson (NYSE:BDX) On Your Watchlist?

Mar 20

Estimating The Intrinsic Value Of Becton, Dickinson and Company (NYSE:BDX)

Mar 05

Becton, Dickinson HPV test Onclarity gets FDA nod for expanded use

Feb 21

Becton, Dickinson wins FDA nod for flu, COVID, RSV combo test

Feb 08

Becton, Dickinson Q1 2023 Earnings Preview

Feb 01

Becton, Dickinson declares $0.91 dividend

Jan 24

Analyse CEO-vergoeding

Hoe is Tom Polen's beloning veranderd ten opzichte van Becton Dickinson's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	US$1b
Mar 31 2024	n/a	n/a	US$1b
Dec 31 2023	n/a	n/a	US$1b
Sep 30 2023	US$17m	US$1m	US$1b
Jun 30 2023	n/a	n/a	US$2b
Mar 31 2023	n/a	n/a	US$2b
Dec 31 2022	n/a	n/a	US$1b
Sep 30 2022	US$17m	US$1m	US$2b
Jun 30 2022	n/a	n/a	US$1b
Mar 31 2022	n/a	n/a	US$1b
Dec 31 2021	n/a	n/a	US$1b
Sep 30 2021	US$14m	US$1m	US$2b
Jun 30 2021	n/a	n/a	US$1b
Mar 31 2021	n/a	n/a	US$1b
Dec 31 2020	n/a	n/a	US$2b
Sep 30 2020	US$12m	US$952k	US$245m
Jun 30 2020	n/a	n/a	US$786m
Mar 31 2020	n/a	n/a	US$923m
Dec 31 2019	n/a	n/a	US$760m
Sep 30 2019	US$6m	US$900k	US$1b
Jun 30 2019	n/a	n/a	US$784m
Mar 31 2019	n/a	n/a	US$926m
Dec 31 2018	n/a	n/a	US$894m
Sep 30 2018	US$6m	US$850k	US$159m

Compensatie versus markt: De totale vergoeding ($USD 17.31M ) Tom } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 13.04M ).

Compensatie versus inkomsten: De vergoeding van Tom is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Tom Polen (51 yo)

7.5yrs

Tenure

US$17,309,938

Compensatie

Mr. Thomas E. Polen, Jr., also known as Tom, serves as Chief Executive Officer and Director at Becton, Dickinson and Company since January 28, 2020. Mr. Polen has been Director at Walgreens Boots Alliance,...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Thomas Polen	President	7.5yrs	US$17.31m	0.020% $ 14.0m
Christopher DelOrefice	Executive VP & CFO	3.1yrs	US$5.21m	0.0044% $ 3.1m
Shana Neal	Executive VP & Chief People Officer	2.5yrs	US$5.89m	0.0057% $ 3.9m
Michael Garrison	Executive VP & President of Medical segment	2.1yrs	US$3.65m	0.0019% $ 1.3m
Thomas Spoerel	Senior VP	5yrs	geen gegevens	0.00071% $ 488.9k
Elizabeth McCombs	Executive VP & Chief Technology Officer	3.5yrs	geen gegevens	geen gegevens
Joseph Smith	Senior VP	2.9yrs	geen gegevens	geen gegevens
Denise Fleming	Executive VP of Technology & Global Services and Chief Information Officer	2.8yrs	geen gegevens	geen gegevens
Greg Rodetis	Head of Investor Relations	less than a year	geen gegevens	geen gegevens
Michelle Quinn	Executive VP & General Counsel	1.7yrs	geen gegevens	0.0017% $ 1.2m
Claudia Curtis	Senior VP	no data	geen gegevens	geen gegevens
Carla Burigatto	Senior VP & Chief Communications Officer	no data	geen gegevens	geen gegevens

2.8yrs

Gemiddelde duur

53yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van BDX wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Thomas Polen	President	4.8yrs	US$17.31m	0.020% $ 14.0m
Joseph Smith	Senior VP	2.9yrs	geen gegevens	geen gegevens
John DeFord	Co-Chair of Scientific Advisory Board	3.4yrs	geen gegevens	geen gegevens
Robert Eckert	Independent Director	8.1yrs	US$362.77k	0.0028% $ 1.9m
Timothy Ring	Independent Director	7.8yrs	US$332.78k	0.020% $ 14.1m
Jeffrey Henderson	Independent Director	6.2yrs	US$357.78k	0.0019% $ 1.3m
Christopher Ian Jones	Independent Director	14.3yrs	US$362.78k	0.0074% $ 5.1m
Bertram Scott	Lead Independent Director	22.1yrs	US$372.78k	0.012% $ 8.4m
Catherine Burzik	Independent Director	11.8yrs	US$357.78k	0.0046% $ 3.2m
William Brown	Independent Director	2.7yrs	US$332.78k	0.00087% $ 599.0k
Claire Fraser-Liggett	Member of Scientific Advisory Board & Independent Director	17.9yrs	US$340.15k	0.0078% $ 5.4m
Carrie Byington	Independent Director	3yrs	US$337.78k	0.00099% $ 681.7k

7.0yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van BDX wordt beschouwd als ervaren (gemiddelde ambtstermijn 7 jaar).

Becton Dickinson Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

BD Names Michael Feld as President of Life Sciences Segment, Effective August 20, 2024

Dave Hickey Retires as Executive Vice President and President of the Life Sciences Segment for BD, Effective from July 1, 2024

Becton, Dickinson and Company, Annual General Meeting, Jan 23, 2024

Becton, Dickinson and Company Announces Executive Changes

BD Names Greg Rodetis as Senior Vice President of Investor Relations

Becton, Dickinson and Company Elects Joanne Waldstreicher to the Board and as Member of the Corporate Governance and Nominating Committee and the Quality and Regulatory Committee of the Board

Recent updates

Becton, Dickinson and Company Reaches Multi-Year Settlement in Hernia Mesh Lawsuits

Here's Why Becton Dickinson (NYSE:BDX) Can Manage Its Debt Responsibly

Becton, Dickinson and Company: Future Benefit From GLP-1 Drug Delivery

Becton, Dickinson and Company (NYSE:BDX) completed the acquisition of Critical Care Product Group of Edwards Lifesciences Corporation (NYSE : EW).

Upcoming dividend of US$0.95 per share

BD Names Michael Feld as President of Life Sciences Segment, Effective August 20, 2024

Becton, Dickinson And Company: Somewhat Undervalued, A Very Moderate Buy

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Becton, Dickinson and Company Updates Earnings Guidance for the Year 2024

Second quarter dividend of US$0.95 announced

Becton, Dickinson and Company Declares Quarterly Dividend, Payable on September 30, 2024

Why We're Not Concerned About Becton, Dickinson and Company's (NYSE:BDX) Share Price

Becton, Dickinson and Company to Report Q3, 2024 Results on Aug 01, 2024

An Intrinsic Calculation For Becton, Dickinson and Company (NYSE:BDX) Suggests It's 36% Undervalued

BD (Becton, Dickinson and Company) Announces the Commercial Launch of a New Single-Cell Research Tool

Becton, Dickinson and Company (NYSE:BDX) entered into an agreement to acquire Critical Care Product Group of Edwards Lifesciences Corporation (NYSE : EW) for $4.2 billion.

Upcoming dividend of US$0.95 per share

Is Becton Dickinson (NYSE:BDX) Using Too Much Debt?

Becton, Dickinson and Company: Stagnating All Along

Becton, Dickinson and Company Revises Earnings Guidance for the Fiscal Year 2024

Second quarter 2024 earnings: EPS exceeds analyst expectations

Becton, Dickinson and Company Declares Quarterly Dividend, Payable on June 28, 2024

Becton, Dickinson and Company (NYSE:BDX) acquired FlowJo LLC.

Becton, Dickinson and Company to Report Q2, 2024 Results on May 02, 2024

Investors Still Waiting For A Pull Back In Becton, Dickinson and Company (NYSE:BDX)

Becton, Dickinson and Company Initiates International Study to Expand Treatment Options for Patients with Peripheral Arterial Disease

Dave Hickey Retires as Executive Vice President and President of the Life Sciences Segment for BD, Effective from July 1, 2024

Estimating The Fair Value Of Becton, Dickinson and Company (NYSE:BDX)

Upcoming dividend of US$0.95 per share

Becton Dickinson's (NYSE:BDX) Conservative Accounting Might Explain Soft Earnings

Becton, Dickinson and Company Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

First quarter 2024 earnings: EPS exceeds analyst expectations

Becton, Dickinson and Company Raises Earnings Guidance for the Fiscal Year of 2024

These 4 Measures Indicate That Becton Dickinson (NYSE:BDX) Is Using Debt Reasonably Well

Fourth quarter dividend of US$0.95 announced

Becton, Dickinson and Company Declares Quarterly Dividend, Payable on March 29, 2024

Becton, Dickinson: 4 Reasons To Buy This Growth At A Reasonable Price Play

Becton, Dickinson and Company to Report Q1, 2024 Results on Feb 01, 2024

Becton, Dickinson and Company, Annual General Meeting, Jan 23, 2024

BD Receives FDA 510(K) Clearance for Potentially Transformative Fingertip Blood Collection Device

Becton Dickinson's (NYSE:BDX) Shareholders Will Receive A Bigger Dividend Than Last Year

BD Launches Advanced Vascular Access Ultrasound System Designed to Improve Clinician Efficiency

Upcoming dividend of US$0.95 per share at 1.6% yield

Becton, Dickinson and Company Announces Executive Changes

Full year 2023 earnings: EPS misses analyst expectations

Becton, Dickinson And Company: Strong Q4 But Clouded By 75bps Growth Headwind From China In FY24

Becton Dickinson's (NYSE:BDX) Upcoming Dividend Will Be Larger Than Last Year's

Becton, Dickinson and Company Increases Quarterly Dividend, Payable on December 29, 2023

Consensus EPS estimates fall by 20%

Becton, Dickinson and Company Provides Earnings Guidance for the Fiscal Year 2024

Becton, Dickinson and Company's (NYSE:BDX) Intrinsic Value Is Potentially 26% Above Its Share Price

Becton, Dickinson and Company Announces Launch of Next-Generation Needle-Free Blood Draw Technology

BD Names Greg Rodetis as Senior Vice President of Investor Relations

Becton, Dickinson and Company to Report Q4, 2023 Results on Nov 09, 2023

Now 21% undervalued

With EPS Growth And More, Becton Dickinson (NYSE:BDX) Makes An Interesting Case

Becton, Dickinson Stock Is A Hold, Here's Why

Now 20% undervalued

Upcoming dividend of US$0.91 per share at 1.3% yield

Becton, Dickinson: Ahead Of Schedule, Undervalued, And With Some Positive Drivers

We Think Becton Dickinson (NYSE:BDX) Can Stay On Top Of Its Debt

Becton, Dickinson and Company Raises Earnings Guidance for the Fiscal Year 2023

New minor risk - Earnings quality

Third quarter 2023 earnings: EPS misses analyst expectations

Estimating The Intrinsic Value Of Becton, Dickinson and Company (NYSE:BDX)

Becton, Dickinson and Company Elects Joanne Waldstreicher to the Board and as Member of the Corporate Governance and Nominating Committee and the Quality and Regulatory Committee of the Board

Becton, Dickinson and Company Receives FDA 510(k) Clearance for Updated BD Alaris™? Infusion System

Becton, Dickinson and Company to Report Q3, 2023 Results on Aug 03, 2023

Here's Why We Think Becton Dickinson (NYSE:BDX) Is Well Worth Watching